New cocktail aims to make inoperable liver metastases removable
NCT ID NCT07649473
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy and radiation can shrink liver tumors from colon cancer enough to allow surgery. About 30 adults with colon cancer that has spread only to the liver will receive the combination before planned surgery. The goal is to see if more patients can achieve complete removal of all visible cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (Iparomlimab/Tuvonralimab) combined with CAPOX chemotherapy and bevacizumab, plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this approach could help more patients with colon cancer that has spread to the liver become eligible for surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase study with only 30 participants and no comparison group. The combination therapy may cause significant side effects, and it is not yet known if it will improve survival or cure rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••